The Synthesis and Metabolism of Steroid Hormones

Yen and Jaffe's Reproductive Endocrinology: Seventh Edition

Volumn , Issue , 2013, Pages 66-92

  Strauss, Jerome F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903238634     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-2758-2.00004-4     Document Type: Chapter

References (152)

1. Umetani M., Shaul P.W. 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol Metab 2011, 22(4):130-135.
2. Nixon M., Upreti R., Andrew R. 5α-Reduced glucocorticoids: a story of natural selection. J Endocrinol 2012, 212(2):111-127.
3. Hu J., Zhang Z., Shen W.J., Azhar S. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 2010 Jun, 1(7):47.
4. Rainey W.E. Adrenal zonation: clues from 11β-hydroxylase and aldosterone synthase. Mol Cell Endocrinol 1999, 151:151-160.
5. Miller W.L., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res 2011, 52(12):2111-2135.
6. Miller W.L., Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011, 32(1):81-151.
7. Conley A.J., Corbin C.J., Thomas J.L., et al. Costs and consequences of cellular compartmentalization and substrate competition among human enzymes involved in androgen and estrogen synthesis. Biol Reprod 2012, 86(1):1-8.
8. Rainey W.E., Carr B.R., Sasano H., et al. Dissecting human adrenal androgen production. Trends Endocrinol Metab 2002, 13:234.
9. Hoekstra M., Van Eck M., Korporaal S.J. Genetic studies in mice and humans reveal new physiological roles for the high-density lipoprotein receptor scavenger receptor class B type I. Curr Opin Lipidol 2012 Jan 18.
10. Kraemer F.B. Adrenal cholesterol utilization. Mol Cell Endocrinol 2007, 265-266:42-45.
11. Ohta K., Sekiya M., Uozaki H., et al. Abrogation of neutral cholesterol ester hydrolytic activity causes adrenal enlargement. Biochem Biophys Res Commun 2011, 404(1):254-260.
12. Illingworth D.R., Corbin D.K., Kemp E.D., et al. Hormone changes during the menstrual cycle in abetalipoproteinemia: reduced luteal phase progesterone in a patient with homozygous hypobetalipoproteinemia. Proc Natl Acad Sci U S A 1982, 79:6685.
13. Parker C., Illingworth D.R., Bissonnette J., et al. Endocrine changes during pregnancy in a patient with homozygous familial hypobetalipoproteinemia. N Engl J Med 1986, 314:557.
14. Plotkin D., Miller S., Nakajima S., et al. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-metyhylglutaryl-coenzyme A reductase inhibitor, does not affect luteal function in premenopausal women. J Clin Endocrinol Metab 2002, 87:3155.
15. Laue L., Hoeg J., Barnes K., et al. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway. J Clin Endocrinol Metab 1987, 64:531.
16. Porter F.D., Herman G.E. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res 2011, 52(1):6-34.
17. Andersson H.C., Frentz J., Martinez J.E., et al. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. Am J Med Genet 1999, 82:382.
18. Shackleton C.H., Roitman E., Kratz L.E., et al. Equine type estrogens produced by a pregnant woman carrying a Smith-Lemli-Opitz syndrome fetus. J Clin Endocrinol Metab 1995, 84:1157.
19. Chang T.Y., Chang C.C.Y., Chen D. Acyl-coenzyme A: cholesterol acyltransferase. Annu Rev Biochem 1997, 66:613.
20. Brasaemle D.L. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res 2007, 48:2547.
21. Wang H., Sreenevasan U., Hu H., et al. Perilipin 5, a lipid droplet-associated protein, provides physical and metabolic linkage to mitochondria. J Lipid Res 2011, 52(12):2159-2168.
22. Kraemer F., Shen W., Natu V., et al. Adrenal neutral cholesteryl ester hydrolase: identification, subcellular distribution, and sex difference. Endocrinology 2002, 143:801.
23. Li H., Brochu M., Wang S.P., et al. Hormone-sensitive lipase deficiency in mice causes lipid storage in the adrenal cortex and impaired corticosterone response to corticotropin stimulation. Endocrinology 2002, 143:3333.
24. Strauss J.F., Schuler L.A., Rosenblum M.F., et al. Cholesterol metabolism by ovarian tissue. Adv Lipid Res 1981, 18:99.
25. Ye J., DeBose-Boyd R.A. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol 2011, 3(7). pii: a00475410.1101/cshperspect.a004754.
26. Brown A.J., Jessup W. Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 2009, 30(3):111-122.
27. Cummins C.L., Volle D.H., Zhang Y., et al. Liver X receptors regulate adrenal cholesterol balance. J Clin Invest 2006, 116(7):1902-1912.
28. Devoto L., Fuentes A., Kohen P., et al. The human corpus luteum: life cycle and function in natural cycles. Fertil Steril 2009, 92(3):1067-1079.
29. Bogan R.L., Hennebold J.D. The reverse cholesterol transport system as a potential mediator of luteolysis in the primate corpus luteum. Reproduction 2010, 139(1):163-176.
30. Penning T.M. Human hydroxysteroid dehydrogenases and pre-receptor regulation: insights into inhibitor design and evaluation. J Steroid Biochem Mol Biol 2011, 125(1-2):46-56.
31. Bose H.S., Sugawara T., Strauss J.F., et al. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1870, 1996:335.
32. Lavigne P., Najmanivich R., Lehoux J.G. Mammalian StAR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. Subcell Biochem 2010, 51:425-437.
33. Heyl B.L., Tyrell D.J., Lambeth J.D. Cytochrome P-450scc-substrate interactions: roles of the 3-band side-chain hydroxyls in binding to oxidized and reduced forms of the enzyme. J Biol Chem 1986, 261:2743.
34. Lambeth J.D., Seybert D.W., Kamin H. Phospholipid vesicle-reconstituted cytochrome P-450scc: mutually facilitated binding of cholesterol and adrenodoxin. J Biol Chem 1980, 255:138.
35. Katsumata N., Ohtake M., Hojo T., et al. Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J Clin Endocrinol Metab 2002, 87:3808.
36. Hiort O., Holterhus P.M., Werner R., et al. Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46, XY sex reversal, and severe adrenal failure. J Clin Endocrinol Metab 2005, 90:538.
37. Hauffa B., Hiort O. P450 side-chain cleavage deficiency-a rare cause of congenital adrenal hyperplasia. Endocr Dev. 2011, 20:54-62.
38. Krone N., Reisch N., Idkowiak J., et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 2011 Dec 7.
39. Miller W.L. The syndrome of 17,20 lyase deficiency. J Clin Endocrinol Metab 2012, 97(1):59-67.
40. Auchus R.J., Lee T.C., Miller W.L. Cytochrome b5 augments the 17, 20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998, 273:3158.
41. Zhang L., Rodriguez H., Ohno S., et al. Serine phosphorylation of human P450c17 increases 17,20 lyase activity: implications for adrenarche and for polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995, 92:10619.
42. Cascio C., Prasad V.V., Lin Y.Y., et al. Detection of P450c17-independent pathways for dehydroepiandrosterone (DHEA) biosynthesis in brain glial tumor cells. Proc Natl Acad Sci U S A 1998, 2862:95.
43. Sohl C.D., Guengerich F.P. Kinetic analysis of the three-step steroid aromatase reaction of human cytochrome P450 19A1. J Biol Chem 2010 Jun 4, 285(23):17734-17743.
44. Kamat A., Hinshelwood M.M., Murry B.A., et al. Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 2002, 13:122.
45. Bulun S.E. Clinical review 78: aromatase deficiency in women and men. Would you have predicted the phenotypes?. J Clin Endocrinol Metab 1996, 81:867.
46. Belgorosky A., Guercio G., Pepe C., Saraco N., Rivarola M.A. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res. 2009, 72(6):321-330.
47. Rochira V., Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol 2009, 5(10):559-568.
48. Simpson E., Clyne C. Rubin, C: Aromatase: a brief overview. Annu Rev Physiol 2002, 64:93.
49. Stratakis C.A., Vottero A., Brodie A., et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998, 83:1348.
50. Bulun S.E., Noble L.S., Takayama K., et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1997, 61:133.
51. Shozu M., Sebastian S., Takayama K., et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003, 1855:348.
52. Fukami M., Shozu M., Soneda S., et al. Aromatase excess syndrome: identification of cryptic duplications and deletions leading to gain of function of CYP19A1 and assessment of phenotypic determinants. J Clin Endocrinol Metab 2011, 96(6):E1035-E1043.
53. Krone N., Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Endocrinol Metab 2009, 23(2):181-192.
54. White P., Rainey W. Steroid 11β-hydroxylase isozymes. Genetics of steroid biosynthesis and function 2002, 179-208. Taylor & Francis, London. J.I. Mason (Ed.).
55. Wendell A. Molecular genetics of 21-hydroxylase deficiency. Endrocr Dev 2011, 20:80-87.
56. Koppens P.F., Hoogenboezem T., Degenhart H.J. Carriership of a defective tenascin-X gene in steroid 21-hydroxylase deficiency patients: TNXB-TNXA hybrids in apparent large-scale gene conversions. Hum Mol Genet 2002, 11:2581.
57. Saloniemi T., Jokela H., Strauss L., et al. The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models. J Endocrinol 2012, 27-40.
58. Lavery G.G., Walker E.A., Tiganescu A., et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008, 93(10):3827-3832.
59. Seckl J.R. 11β-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol 2004, 4(6):597-602.
60. Simard J., Ricketts M.-L., Gingras S., et al. Molecular biology of the 3ß-hydroxysteroid dehydrogenase/Δ5Δ4 isomerase gene family. Endocr Rev 2005, 226:525.
61. Lawson A.J., Walker E.A., Lavery G.G., et al. Cortisone-reductase deficiency associated with heterozygous mutations in 11β-hydroxysteroid dehydrogenase type 1. Proc Natl Acad Sci U S A 2011, 108(10):4111-4116.
62. Kratschmar D.V., Vuorinen A., Da Cunha T., et al. Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting characterization of dehydrogenase type 2. J Steroid Biochem Mol Biol 2011, 125(1-2):129-142.
63. Tanahashi T., Mune T., Morita H., et al. Glycyrrhizic acid suppresses type 2 11β-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol 2002, 80:441.
64. Moeller G., Adamski J. Multifunctionality of human 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006, 248:47.
65. Lukacik P., Kavanagh K.L., Oppermann U. Structure and function of human 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006, 248:61.
66. Marchais-Oberwinkler S., Henn C., Möller G., et al. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol 2011, 125(1-2):66-82.
67. Hong Y., Chen S. Aromatase, estrone sulfatase, and 17β-hydroxysteroid dehydrogenase: structure-function studies and inhibitor development. Mol Cell Endocrinol 2011, 340(2):120-126.
68. George M.M., New M.I., Ten S., et al. The clinical and molecular heterogeneity of 17βHSD-3 enzyme deficiency. Horm Res Paediatr 2010, 74(4):229-240.
69. Luu-The V., Dufort I., Pelletier G., et al. Type 5 17β-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol Cell Endocrinol 2001, 171:77.
70. Nelson V.L., Qin K.N., Rosenfield R.L., et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:5925.
71. Flück C.E., Meyer-Böni M., Pandey A.V., et al. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet 2011, 89(2):201-218.
72. Russell D.W., Wilson J.D. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994, 63:25.
73. Wilson J.D., Griffin J.E., Russell D.W. Steroid 5-reductase 2 deficiency. Endocr Rev 1993, 14:577.
74. Mahendroo M.S., Cala K., Russell D.W. 5α-Reduced androgens play a key role in murine parturition. Mol Endocrinol 1996, 10:380.
75. Mahendroo M.S., Cala K.M., Landrum D.P., et al. Fetal death in mice lacking 5α-reductase type 1 caused by estrogen excess. Mol Endocrinol 1997, 11:917.
76. Kondo K., Kai M., Setoguchi Y., et al. Cloning and expression of cDNA of human 4-4-3-oxosteroid-5β-reductase and substrate specificity of the expressed enzyme. Eur J Biochem 1994, 219:357.
77. Negishi M., Pedersen L.G., Petrotchenko E., et al. Structure and function of sulfotransferases. Arch Biochem Biophys 2001, 390:149.
78. Fuda H., Lee Y.C., Shimizu C., et al. Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J Biol Chem 2002, 277:36161.
79. Suzuki T., Miki Y., Nakamura Y., et al. Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Mol Cell Endocrinol 2011 Jul 4, 340(2):148-153.
80. Qian Y.M., Sun X.J., Tong M.H., et al. Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation. Endocrinology 2001, 142:5342.
81. Kester M.H., Bulduk S., Tibboel D., et al. Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology 2000, 1897:141.
82. Purohit A., Woo L.W. Potter BV: Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol 2011, 340(2):154-160.
83. Yen P.H., Li X.M., Tsai S.P., et al. Frequent deletions of the human X chromosome distal short arm result from recombination between low copy repetitive elements. Cell 1990, 61:603.
84. Ballabio A., Carrozzo R., Parenti G., et al. Molecular heterogeneity of steroid sulfatase deficiency: a multicenter study on 57 unrelated patients, at DNA and protein levels. Genomics 1989, 4:36.
85. Foster P.A., Purohit A. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol 2012, 212(2):99-110.
86. Albert C., Barbier O., Vallee M., et al. Distribution of uridine diphosphate-glucuronosyltransferase (UGT) expression and activity in cynomolgus monkey tissues: evidence for differential expression of steroid-conjugating UGT enzymes in steroid target tissues. Endocrinology 2000, 141:2472.
87. Turgeon D., Carrier J.S., Levesque E., et al. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001, 142:778.
88. Levesque E., Turgeon D., Carrier J.S., et al. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 2001, 40:3869.
89. Kohalmy K., Vrzal R. Regulation of phase II biotransformation enzymes by steroid hormones. Curr Drug Metab 2011, 12(2):104-123.
90. Barbier O., Bélanger A. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 2008, 22(2):259-270.
91. Weisz J., Clawson G.A., Creveling C.R. Biogenesis and inactivation of catecholestrogens. Adv Pharmacol 1998, 42:828.
92. Cavalieri E., Frenkel K., Liehr J.G., et al. Estrogens as endogenous genotoxic agents: DNA adducts and mutations. J Natl Cancer Inst Monogr 2000, 27:75.
93. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 2003, 15:425.
94. Kanasaki K., Palmsten K., Sugimoto H., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008 Jun 19, 453(7198):1117-1121.
95. Hill L.D., York T.P., Kusanovic J.P., et al. Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One 2011 Jan 31, 6(1):e16681.
96. Hochberg R.B., Pahuja S.L., Zielinski J.E., et al. Steroidal fatty acid esters. J Steroid Biochem Mol Biol 1991, 40:577.
97. Vihma V., Tikkanen M.J. Fatty acid esters of steroids: synthesis and metabolism in lipoproteins and adipose tissue. J Steroid Biochem Mol Biol 2011, 124(3-5):65-76.
98. Chalbot S., Morfin R. Dehydroepiandrosterone metabolites and their interactions in humans. Drug Metabol Drug Interact 2006, 22(1):1-23.
99. Foster S.J., Marshall D.E., Houghton E., Gower D.B. Investigations into the biosynthetic pathways for classical and ring B-unsaturated oestrogens in equine placental preparations and allantochorionic tissues. J Steroid Biochem Mol Biol 2002, 82(4-5):401-411.
100. Christakos S., Ajibade D.V., Dhawan P., Fechner A.J., Mady L.J. Vitamin D: metabolism. Endocrinol Metab Clin North Am 2010, 39(2):243-253.
101. Henry H.L. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011, 25(4):531-541.
102. Tsai L.C., Beavo J.A. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol 2011, 11(6):670-675.
103. Schimmer B.P., White P.C. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol Endocrinol 2010, 24(7):1322-1337.
104. Ferraz-de-Souza B., Lin L., Achermann J.C. Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol Cell Endocrinol 2011, 336(1-2):198-205.
105. Fayard E., Auwerx J., Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol 2004, 14:250.
106. Krylova I.N., Sablin E.P., Moore J., et al. Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell 2005, 120:343.
107. Martin L.J., Taniguchi H., Robert N.M., et al. GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3β-hydroxysteroid dehydrogenase type 2 promoter. Mol Endocrinol 2005, 19:2358-2370.
108. King S.R., Lavoie H.A. Gonadal transactivation of STARD1, CYP11A1 and HSD3B. Front Biosci 2012, 1(17):824-846.
109. Tuckey R.C. Progesterone synthesis by the human placenta. Placenta 2005, 26:273.
110. Luu-The V., Labrie F. The intracrine sex steroid biosynthesis pathways. Prog Brain Res 2010, 177-192.
111. Lathe R., Seckl J. Neurosteroids and brain sterols. Genetics of steroid biosynthesis and function 2002, 407-474. Taylor & Francis, London. J.I. Mason (Ed.).
112. Attar E., Bulun S.E. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006, 12:49-56.
113. Mellon S.H., Griffin L.D. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002, 13:35.
114. Pelletier G. Steroidogenic enzymes in the brain: morphological aspects. Prog Brain Res 2010, 181:193-207.
115. Deplewski D., Rosenfield R.L. Role of hormones in pilosebaceous unit development. Endocr Rev 2002, 21:363.
116. Couzinet B., Meduri G., Lecce M.G., et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001, 86:5060.
117. Tait J.F. The use of isotopic steroids for the measurement of production rates in vivo. J Clin Endocrinol Metab 1963, 23:1285.
118. Milewich L., Parker P.S., MacDonald P.C. Testosterone metabolism by human lung tissue. J Steroid Biochem 1978, 9:29.
119. Milewich L., Smith S.L., MacDonald P.C. Nonrespiratory functions of the human lung: in vitro metabolism of tritium-labeled progesterone and pregnenolone. J Clin Endocrinol Metab 1980, 50:507.
120. Dunn J.F., Nisula B.C., Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticoid-binding globulin in human plasma. J Clin Endocrinol Metab 1981, 53:58.
121. Sitteri P.K., Murai J.T., Hammond G.L., et al. The serum transport of steroid hormones. Recent Prog Horm Res 1982, 38:457.
122. Manni A., Pardridge W.M., Cefalu W., et al. Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 1985, 61:705.
123. Baird D.T., Horton R., Longcope C., et al. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969, 25:611.
124. Hogeveen K.N., Cousin P., Pugeat M., et al. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Invest 2002, 109:973.
125. Ukkola O., Rankinen T., Gagnon J., et al. A genome-wide linkage scan for steroids and SHBG levels in black and white families: the HERITAGE Family Study. J Clin Endocrinol Metab 2002, 87:3708.
126. Cousin P., Calemard-Michel L., Lejeune H., et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 2004, 89:917.
127. Le T.N., Nestler J.E., Strauss J.F., Wickham E.P. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 2012, 23(1):32-40.
128. Hammond G.L. Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 2011, 85(3):431-441.
129. Craig Z.R., Wang W., Flaws J.A. Endocrine-disrupting chemicals in ovarian function: effects on steroidogenesis, metabolism and nuclear receptor signaling. Reproduction 2011, 142:633-646.
130. Shaw M.A., Nicholls P.J., Smith H.J. Aminoglutethimide and ketoconazole: historical perspectives and future prospects. J Steroid Biochem 1988, 31:137.
131. Bryce A., Ryan C.J. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther 2012 Jan, 91(1):101-108.
132. Engelhardt D., Weber M.M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994, 49:261.
133. Chumsri S., Howes T., Bao T., Sabnis G., Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011, 125(1-2):13-22.
134. Bull H.G., Gacia-Calvo M., Andersson S., et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 1996, 118:2359.
135. Goldman A.S. Further studies of steroidal inhibitors of delpha5, 3beta-hydroxysteroid dehydrogenase and delta5-delta4, 3-ketosteroid isomerase in Pseudomonas testosteroni and in bovine adrenals. J Clin Endocrinol Metab 1968, 28:1539.
136. Christiansen R.G., Neumann H.G., Salvador U.J., et al. Steroidogenesis inhibitors: adrenal inhibitory and interceptive activity of trilostane and related compounds. J Med Chem 1984, 27:928.
137. Blum A., Favia A.D., Maser E. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Mol Cell Endocrinol 2009, 301(1-2):132-136.
138. Gibbs J.P., Emery M.G., McCaffery I., et al. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol 2011, 51(6):830-841.
139. de Gooyer M.E., Kleyn G.T., Smits K.C., et al. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001, 183:55.
140. Auchus M.L., Auchus R.J. Human steroid biosynthesis for the oncologist. J Investig Med 2012, 60(2):495-503.
141. Baird D.T., Horton R., Longcope C., et al. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969, 25:611.
142. Blair I.A. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 2010, 75(4-5):297-306.
143. Hammond G.L. Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 2011, 85(3):431-441.
144. Henry H.L. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011, 25(4):531-541.
145. King S.R., Lavoie H.A. Gonadal transactivation of STARD1, CYP11A1 and HSD3B. Front Biosci 2012, 1(17):824-846.
146. Lerchbaum E., Obermayer-Pietsch B. Vitamin D and fertility: a systematic review. Eur J Endocrinol 2012, 166(5):765-778.
147. Miller W.L., Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011, 32(1):81-151.
148. Miller W.L., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res 2011, 52(12):2111-2135.
149. Nimkarn S., Lin-Su K., New M.I. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2009, 38(4):699-718.
150. Penning T.M. Human hydroxysteroid dehydrogenases and pre-receptor regulation: insights into inhibitor design and evaluation. J Steroid Biochem Mol Biol 2011, 125(1-2):46-56.
151. Stocco C. Tissue physiology and pathology of aromatase. Steroids 2012, 77(1-2):27-35.
152. Ye J., DeBose-Boyd R.A. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol 2011, 3(7). pii: a004754. doi:10.1101/cshperspect.a004754.